Best Medications for PTSD
For adult PTSD, selective serotonin reuptake inhibitors (SSRIs)—specifically sertraline or paroxetine—are the recommended first-line pharmacological treatments, with venlafaxine as an alternative option. 1, 2
First-Line Pharmacotherapy
The 2024 VA/DoD Clinical Practice Guideline provides the most authoritative and recent guidance, making a strong recommendation for three specific medications when pharmacotherapy is indicated 1:
- Paroxetine
- Sertraline
- Venlafaxine
These agents have demonstrated moderate-certainty evidence for improving PTSD symptoms. In clinical trials, SSRIs improved symptoms in approximately 58% of participants compared to 35% receiving placebo 2. The Australian guidelines (2022) similarly recommend sertraline, paroxetine, or fluoxetine as first-line agents, with venlafaxine now conditionally recommended alongside these SSRIs 3.
Critical Context: Psychotherapy Takes Priority
An essential caveat: The VA/DoD guideline strongly recommends specific manualized psychotherapies OVER pharmacotherapy as the primary treatment approach 1. Medications should be considered when:
- Trauma-focused psychotherapy is unavailable or not feasible
- The patient prefers medication
- Psychotherapy alone has been insufficient
- Co-occurring conditions warrant pharmacological intervention
The recommended psychotherapies include prolonged exposure, cognitive processing therapy, and eye movement desensitization and reprocessing (EMDR) 1.
Dosing Strategy
Start with standard antidepressant dosing and titrate based on response. For SSRIs, treatment duration should extend 8-12 weeks before assessing full efficacy 4. If partial response occurs, consider dose optimization before switching agents.
Second-Line and Adjunctive Options
When first-line agents fail or are contraindicated, lower-certainty evidence supports 2:
- Mirtazapine (NaSSA): Showed benefit in limited data (65% response vs. 22% placebo) 2
- Amitriptyline (TCA): Demonstrated efficacy (50% response vs. 17% placebo) but with more side effects 2
For PTSD-associated nightmares specifically, multiple agents "may be used" including prazosin, though recent large trials have downgraded its recommendation 5. Other options for nightmares include atypical antipsychotics (olanzapine, risperidone, aripiprazole), topiramate, and trazodone 5.
What NOT to Use
The VA/DoD guideline makes strong recommendations AGAINST 1:
- Benzodiazepines
- Cannabis or cannabis-derived products
Additionally, clonazepam and venlafaxine are specifically not recommended for nightmare disorder 5.
Tolerability Considerations
Dropout rates due to adverse events are relatively low with SSRIs (approximately 9%), though slightly higher than placebo 2. Paroxetine specifically showed increased withdrawal rates (RR 1.55) compared to placebo 2. Monitor for:
- Activation/agitation early in treatment
- Sexual dysfunction
- Gastrointestinal effects
- Weight changes
TCAs like amitriptyline carry higher side effect burden including anticholinergic effects and orthostatic hypotension, making them less suitable as first-line agents despite efficacy 2.
Treatment Duration and Monitoring
Continue effective medication for at least 12 months after symptom remission to prevent relapse 4. Assess response using validated measures (e.g., CAPS-5, PCL-5) at regular intervals. If no response after 8-12 weeks at therapeutic doses, consider switching to an alternative first-line agent rather than augmentation strategies.
The Evidence Landscape
The medication evidence base for PTSD remains modest compared to other psychiatric conditions. Only paroxetine and sertraline have FDA approval specifically for PTSD 6. The overall effect size for antidepressants in PTSD (SMD 0.25) is smaller than in major depressive disorder 7, underscoring why psychotherapy remains the primary recommendation when feasible.